Stereotaxis, Inc. develops robotic technologies for minimally invasive endovascular intervention, with recurring news centered on electrophysiology and arrhythmia treatment. Company updates cover the MAGiC™ Magnetic Interventional Ablation Catheter, MAGiC Sweep high density mapping catheter, Genesis and GenesisX robotic magnetic navigation systems, and related clinical use in complex heart-rhythm procedures.
News also includes FDA and international regulatory clearances or approvals, hospital robotic heart-arrhythmia program launches, commercialization of cath-lab technologies such as Synchrony™ and SynX™, manufacturing and product-pipeline progress, material agreements, capital-structure updates, and periodic operating and financial results.
Stereotaxis (NYSE: STXS) has announced an inaugural Symposium to be held on June 20, 2020, via live interactive webcast. The event will showcase bi-directional TeleRobotic procedures, enabling physicians to navigate catheters from over 1700 km apart. A panel discussion will follow, focusing on enhancing patient care, expanding therapy access, and improving physician education in TeleRobotic Surgery. Furthermore, the TeleRobotic Surgery Leadership Council has been formed to advance remote surgical support. Registration is open to healthcare professionals and industry partners.
Summary not available.